| Abstrakt: |
A recent study conducted in Leiden, Netherlands, explored the effects of guselkumab therapy on the skin barrier function and ceramide profile in patients with psoriasis. The study involved 26 patients who were randomly assigned to receive either guselkumab or a placebo for 16 weeks. The researchers found that guselkumab therapy normalized the ceramide profile and improved the barrier function of the skin in psoriasis patients. The study also revealed a correlation between the ceramide profile, barrier function, and disease severity. These findings highlight the potential of guselkumab therapy in restoring the skin barrier in psoriasis. [Extracted from the article] |
